Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure

A.M. Marra; M. Arcopinto; A. Salzano; Emanuele Bobbio; Salvatore Milano; G. Misiano; F. Ferrara; Olga Vriz; Raffaele Napoli; V. Triggiani; P. Perrone Filardi; F. Saccà; Francesco Giallauria; Andrea M. Isidori; A. C. Vigorito; Eduardo Bossone; Antonio Cittadini

doi:10.1016/j.ijcard.2016.02.017

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure

A.M. Marra, M. Arcopinto, A. Salzano, Emanuele Bobbio, Salvatore Milano, G. Misiano, F. Ferrara, Olga Vriz, Raffaele Napoli, V. Triggiani, P. Perrone Filardi, F. Saccà, Francesco Giallauria, Andrea M. Isidori, A. C. Vigorito, Eduardo Bossone, Antonio Cittadini

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	114-117
Number of pages	4
Journal	International Journal of Cardiology
Volume	209
DOIs	https://doi.org/10.1016/j.ijcard.2016.02.017
Publication status	Published - 2016

Keywords

Chronic heart failure
Cytokines
Interleukin-9
Outcomes
Peak oxygen consumption
Risk stratification
eotaxin
fibroblast growth factor
fibroblast growth factor beta
gamma interferon
gamma interferon inducible protein 10
granulocyte colony stimulating factor
granulocyte macrophage colony stimulating factor
interleukin 1 receptor type I
interleukin 10
interleukin 12p70
interleukin 13
interleukin 15
interleukin 17
interleukin 1beta
interleukin 2
interleukin 4
interleukin 5
interleukin 6
interleukin 7
interleukin 8
interleukin 9
macrophage inflammatory protein 1alpha
macrophage inflammatory protein 1beta
monocyte chemotactic protein 1
platelet derived growth factor
RANTES
unclassified drug
vasculotropin
IL9 protein, human
adult
aged
Article
cardiopulmonary function
cardiovascular mortality
controlled study
female
functional status
heart failure
heart left ventricle ejection fraction
human
major clinical study
male
middle aged
predictive value
priority journal
prognosis
protein blood level
protein function
blood
cause of death
mortality
risk factor
Aged
Cause of Death
Female
Heart Failure
Humans
Male
Middle Aged
Risk Factors

Access to Document

10.1016/j.ijcard.2016.02.017

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961653826&doi=10.1016%2fj.ijcard.2016.02.017&partnerID=40&md5=f7865537681849db335afd7a1586eaca

Cite this

Marra, A. M., Arcopinto, M., Salzano, A., Bobbio, E., Milano, S., Misiano, G., Ferrara, F., Vriz, O., Napoli, R., Triggiani, V., Perrone Filardi, P., Saccà, F., Giallauria, F., Isidori, A. M., Vigorito, A. C., Bossone, E., & Cittadini, A. (2016). Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. International Journal of Cardiology, 209, 114-117. https://doi.org/10.1016/j.ijcard.2016.02.017

Marra, AM, Arcopinto, M, Salzano, A, Bobbio, E, Milano, S, Misiano, G, Ferrara, F, Vriz, O, Napoli, R, Triggiani, V, Perrone Filardi, P, Saccà, F, Giallauria, F, Isidori, AM, Vigorito, AC, Bossone, E & Cittadini, A 2016, 'Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure', International Journal of Cardiology, vol. 209, pp. 114-117. https://doi.org/10.1016/j.ijcard.2016.02.017

@article{fc058f49711b4d10bb01d093d8929613,

title = "Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure",

keywords = "Chronic heart failure, Cytokines, Interleukin-9, Outcomes, Peak oxygen consumption, Risk stratification, eotaxin, fibroblast growth factor, fibroblast growth factor beta, gamma interferon, gamma interferon inducible protein 10, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 1 receptor type I, interleukin 10, interleukin 12p70, interleukin 13, interleukin 15, interleukin 17, interleukin 1beta, interleukin 2, interleukin 4, interleukin 5, interleukin 6, interleukin 7, interleukin 8, interleukin 9, macrophage inflammatory protein 1alpha, macrophage inflammatory protein 1beta, monocyte chemotactic protein 1, platelet derived growth factor, RANTES, unclassified drug, vasculotropin, IL9 protein, human, adult, aged, Article, cardiopulmonary function, cardiovascular mortality, controlled study, female, functional status, heart failure, heart left ventricle ejection fraction, human, major clinical study, male, middle aged, predictive value, priority journal, prognosis, protein blood level, protein function, blood, cause of death, mortality, risk factor, Aged, Cause of Death, Female, Heart Failure, Humans, Male, Middle Aged, Risk Factors",

author = "A.M. Marra and M. Arcopinto and A. Salzano and Emanuele Bobbio and Salvatore Milano and G. Misiano and F. Ferrara and Olga Vriz and Raffaele Napoli and V. Triggiani and {Perrone Filardi}, P. and F. Sacc{\`a} and Francesco Giallauria and Isidori, {Andrea M.} and Vigorito, {A. C.} and Eduardo Bossone and Antonio Cittadini",

note = "Export Date: 21 March 2017 CODEN: IJCDD Correspondence Address: Cittadini, A.; Department of Translational Medical Sciences, Federico II University, Via Pansini 5, Italy; email: antonio.cittadini@unina.it Chemicals/CAS: fibroblast growth factor, 62031-54-3; gamma interferon, 82115-62-6; gamma interferon inducible protein 10, 97741-20-3; interleukin 13, 148157-34-0; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; macrophage inflammatory protein 1alpha, 155075-84-6; macrophage inflammatory protein 1beta, 122071-81-2; vasculotropin, 127464-60-2; IL9 protein, human; Interleukin-9 References: Tabet, J.Y., Lopes, M.E., Champagne, S., Su, J.B., Merlet, P., Hittinger, L., Inflammation, cytokines and anti-inflammatory therapies in heart failure (2002) Arch. Mal. Coeur Vaiss., 95, pp. 204-212. , http://www.ncbi.nlm.nih.gov/pubmed/11998336, accessed November 25, 2015; Cappuzzello, C., Di Vito, L., Melchionna, R., Melillo, G., Silvestri, L., Cesareo, E., Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure (2011) J. Transl. Med., 9, p. 28; Nymo, S.H., Hulthe, J., Ueland, T., McMurray, J., Wikstrand, J., Askevold, E.T., Inflammatory cytokines in chronic heart failure: Interleukin-8 is associated with adverse outcome. Results from CORONA (2014) Eur. J. Heart Fail., 16, pp. 68-75; Cittadini, A., Saldamarco, L., Marra, A.M., Arcopinto, M., Carlomagno, G., Imbriaco, M., Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction (2009) J. Clin. Endocrinol. Metab., 94, pp. 3329-3336; Ferrara, N., Corbi, G., Bosimini, E., Cobelli, F., Furgi, G., Giannuzzi, P., Cardiac rehabilitation in the elderly: Patient selection and outcomes (2006) Am. J. Geriatr. Cardiol., 15, pp. 22-27. , http://www.ncbi.nlm.nih.gov/pubmed/16415643, accessed November 28, 2015; Knoops, L., Renauld, J.-C., IL-9 and its receptor: From signal transduction to tumorigenesis (2004) Growth Factors, 22, pp. 207-215; Cittadini, A., Monti, M.G., Iaccarino, G., Castiello, M.C., Baldi, A., Bossone, E., SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway (2012) Cardiovasc. Res., 96, pp. 381-390; Terrell, A.M., Crisostomo, P.R., Wairiuko, G.M., Wang, M., Morrell, E.D., Meldrum, D.R., Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart (2006) Shock, 26, pp. 226-234; Braunwald, E., Heart failure (2013) JACC Heart Fail., 1, pp. 1-20; Cittadini, A., Ines Comi, L., Longobardi, S., Rocco Petretta, V., Casaburi, C., Passamano, L., A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies (2003) Eur. Heart J., 24, pp. 664-672. , http://www.ncbi.nlm.nih.gov/pubmed/12657225, accessed November 28, 2015; Marra, A.M., Arcopinto, M., Bossone, E., Ehlken, N., Cittadini, A., Gr{\"u}nig, E., Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives (2015) Nutr. Metab. Cardiovasc. Dis., 25, pp. 131-139",

year = "2016",

doi = "10.1016/j.ijcard.2016.02.017",

language = "English",

volume = "209",

pages = "114--117",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure

AU - Marra, A.M.

AU - Arcopinto, M.

AU - Salzano, A.

AU - Bobbio, Emanuele

AU - Milano, Salvatore

AU - Misiano, G.

AU - Ferrara, F.

AU - Vriz, Olga

AU - Napoli, Raffaele

AU - Triggiani, V.

AU - Perrone Filardi, P.

AU - Saccà, F.

AU - Giallauria, Francesco

AU - Isidori, Andrea M.

AU - Vigorito, A. C.

AU - Bossone, Eduardo

AU - Cittadini, Antonio

N1 - Export Date: 21 March 2017 CODEN: IJCDD Correspondence Address: Cittadini, A.; Department of Translational Medical Sciences, Federico II University, Via Pansini 5, Italy; email: antonio.cittadini@unina.it Chemicals/CAS: fibroblast growth factor, 62031-54-3; gamma interferon, 82115-62-6; gamma interferon inducible protein 10, 97741-20-3; interleukin 13, 148157-34-0; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; macrophage inflammatory protein 1alpha, 155075-84-6; macrophage inflammatory protein 1beta, 122071-81-2; vasculotropin, 127464-60-2; IL9 protein, human; Interleukin-9 References: Tabet, J.Y., Lopes, M.E., Champagne, S., Su, J.B., Merlet, P., Hittinger, L., Inflammation, cytokines and anti-inflammatory therapies in heart failure (2002) Arch. Mal. Coeur Vaiss., 95, pp. 204-212. , http://www.ncbi.nlm.nih.gov/pubmed/11998336, accessed November 25, 2015; Cappuzzello, C., Di Vito, L., Melchionna, R., Melillo, G., Silvestri, L., Cesareo, E., Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure (2011) J. Transl. Med., 9, p. 28; Nymo, S.H., Hulthe, J., Ueland, T., McMurray, J., Wikstrand, J., Askevold, E.T., Inflammatory cytokines in chronic heart failure: Interleukin-8 is associated with adverse outcome. Results from CORONA (2014) Eur. J. Heart Fail., 16, pp. 68-75; Cittadini, A., Saldamarco, L., Marra, A.M., Arcopinto, M., Carlomagno, G., Imbriaco, M., Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction (2009) J. Clin. Endocrinol. Metab., 94, pp. 3329-3336; Ferrara, N., Corbi, G., Bosimini, E., Cobelli, F., Furgi, G., Giannuzzi, P., Cardiac rehabilitation in the elderly: Patient selection and outcomes (2006) Am. J. Geriatr. Cardiol., 15, pp. 22-27. , http://www.ncbi.nlm.nih.gov/pubmed/16415643, accessed November 28, 2015; Knoops, L., Renauld, J.-C., IL-9 and its receptor: From signal transduction to tumorigenesis (2004) Growth Factors, 22, pp. 207-215; Cittadini, A., Monti, M.G., Iaccarino, G., Castiello, M.C., Baldi, A., Bossone, E., SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway (2012) Cardiovasc. Res., 96, pp. 381-390; Terrell, A.M., Crisostomo, P.R., Wairiuko, G.M., Wang, M., Morrell, E.D., Meldrum, D.R., Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart (2006) Shock, 26, pp. 226-234; Braunwald, E., Heart failure (2013) JACC Heart Fail., 1, pp. 1-20; Cittadini, A., Ines Comi, L., Longobardi, S., Rocco Petretta, V., Casaburi, C., Passamano, L., A preliminary randomized study of growth hormone administration in Becker and Duchenne muscular dystrophies (2003) Eur. Heart J., 24, pp. 664-672. , http://www.ncbi.nlm.nih.gov/pubmed/12657225, accessed November 28, 2015; Marra, A.M., Arcopinto, M., Bossone, E., Ehlken, N., Cittadini, A., Grünig, E., Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives (2015) Nutr. Metab. Cardiovasc. Dis., 25, pp. 131-139

PY - 2016

Y1 - 2016

KW - Chronic heart failure

KW - Cytokines

KW - Interleukin-9

KW - Outcomes

KW - Peak oxygen consumption

KW - Risk stratification

KW - eotaxin

KW - fibroblast growth factor

KW - fibroblast growth factor beta

KW - gamma interferon

KW - gamma interferon inducible protein 10

KW - granulocyte colony stimulating factor

KW - granulocyte macrophage colony stimulating factor

KW - interleukin 1 receptor type I

KW - interleukin 10

KW - interleukin 12p70

KW - interleukin 13

KW - interleukin 15

KW - interleukin 17

KW - interleukin 1beta

KW - interleukin 2

KW - interleukin 4

KW - interleukin 5

KW - interleukin 6

KW - interleukin 7

KW - interleukin 8

KW - interleukin 9

KW - macrophage inflammatory protein 1alpha

KW - macrophage inflammatory protein 1beta

KW - monocyte chemotactic protein 1

KW - platelet derived growth factor

KW - RANTES

KW - unclassified drug

KW - vasculotropin

KW - IL9 protein, human

KW - adult

KW - aged

KW - Article

KW - cardiopulmonary function

KW - cardiovascular mortality

KW - controlled study

KW - female

KW - functional status

KW - heart failure

KW - heart left ventricle ejection fraction

KW - human

KW - major clinical study

KW - male

KW - middle aged

KW - predictive value

KW - priority journal

KW - prognosis

KW - protein blood level

KW - protein function

KW - blood

KW - cause of death

KW - mortality

KW - risk factor

KW - Aged

KW - Cause of Death

KW - Female

KW - Heart Failure

KW - Humans

KW - Male

KW - Middle Aged

KW - Risk Factors

U2 - 10.1016/j.ijcard.2016.02.017

DO - 10.1016/j.ijcard.2016.02.017

M3 - Article

SN - 0167-5273

VL - 209

SP - 114

EP - 117

JO - International Journal of Cardiology

JF - International Journal of Cardiology

ER -